Drug profile · INN
vestronidase alfa
MEPSEVII
vestronidase alfa (MEPSEVII) is a glycosaminoglycans hydrolytic enzyme. Associated with Ultragenyx UK Limited.
EMA: approved Alimentary tract and metabolism (A16) A16AB18
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — vestronidase alfa
- Class
- Alimentary tract and metabolism (A16)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
vestronidase alfa (MEPSEVII) is a glycosaminoglycans hydrolytic enzyme. Associated with Ultragenyx UK Limited.
Key facts
INN vestronidase alfa
Brand MEPSEVII
Mechanism Glycosaminoglycans hydrolytic enzyme
Target Glycosaminoglycans
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16AB18
Originator Ultragenyx UK Limited
Mechanism of action
Glycosaminoglycans hydrolytic enzyme
Primary target: Glycosaminoglycans
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is vestronidase alfa?
vestronidase alfa (MEPSEVII) is a glycosaminoglycans hydrolytic enzyme. Associated with Ultragenyx UK Limited.
What is the brand name for vestronidase alfa?
MEPSEVII is a marketed brand name for vestronidase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.